94 related articles for article (PubMed ID: 15019215)
1. Inhibition of Staphylococcus aureus pathogenesis in vitro and in vivo by RAP-binding peptides.
Yang G; Cheng H; Liu C; Xue Y; Gao Y; Liu N; Gao B; Wang D; Li S; Shen B; Shao N
Peptides; 2003 Nov; 24(11):1823-8. PubMed ID: 15019215
[TBL] [Abstract][Full Text] [Related]
2. A novel peptide isolated from phage library to substitute a complex system for a vaccine against staphylococci infection.
Yang G; Gao Y; Dong J; Xue Y; Fan M; Shen B; Liu C; Shao N
Vaccine; 2006 Feb; 24(8):1117-23. PubMed ID: 16359760
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating Protein (TRAP).
Balaban N; Goldkorn T; Gov Y; Hirshberg M; Koyfman N; Matthews HR; Nhan RT; Singh B; Uziel O
J Biol Chem; 2001 Jan; 276(4):2658-67. PubMed ID: 11160124
[TBL] [Abstract][Full Text] [Related]
4. Characterization of RAP, a quorum sensing activator of Staphylococcus aureus.
Korem M; Sheoran AS; Gov Y; Tzipori S; Borovok I; Balaban N
FEMS Microbiol Lett; 2003 Jun; 223(2):167-75. PubMed ID: 12829282
[TBL] [Abstract][Full Text] [Related]
5. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus.
Balaban N; Goldkorn T; Nhan RT; Dang LB; Scott S; Ridgley RM; Rasooly A; Wright SC; Larrick JW; Rasooly R; Carlson JR
Science; 1998 Apr; 280(5362):438-40. PubMed ID: 9545222
[TBL] [Abstract][Full Text] [Related]
6. A novel peptide screened by phage display can mimic TRAP antigen epitope against Staphylococcus aureus infections.
Yang G; Gao Y; Dong J; Liu C; Xue Y; Fan M; Shen B; Shao N
J Biol Chem; 2005 Jul; 280(29):27431-5. PubMed ID: 15908434
[TBL] [Abstract][Full Text] [Related]
7. Novel DNA binding protein SarZ contributes to virulence in Staphylococcus aureus.
Kaito C; Morishita D; Matsumoto Y; Kurokawa K; Sekimizu K
Mol Microbiol; 2006 Dec; 62(6):1601-17. PubMed ID: 17087772
[TBL] [Abstract][Full Text] [Related]
8. Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection.
Cui JC; Hu DL; Lin YC; Qian AD; Nakane A
FEMS Immunol Med Microbiol; 2005 Jul; 45(1):45-51. PubMed ID: 15985222
[TBL] [Abstract][Full Text] [Related]
9. Treatment efficacy of the lead RNAIII-inhibiting peptide YSPWTNF-NH2 in acquired Staphylococcus aureus sepsis: a histopathological assessment.
Ribeiro PD; Ribeiro OD; Marcolan AM; Medina-Acosta E
Peptides; 2003 Nov; 24(11):1829-36. PubMed ID: 15019216
[TBL] [Abstract][Full Text] [Related]
10. Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide.
Dell'Acqua G; Giacometti A; Cirioni O; Ghiselli R; Saba V; Scalise G; Gov Y; Balaban N
J Infect Dis; 2004 Jul; 190(2):318-20. PubMed ID: 15216467
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of complement activation by a secreted Staphylococcus aureus protein.
Lee LY; Höök M; Haviland D; Wetsel RA; Yonter EO; Syribeys P; Vernachio J; Brown EL
J Infect Dis; 2004 Aug; 190(3):571-9. PubMed ID: 15243934
[TBL] [Abstract][Full Text] [Related]
12. RNAIII Inhibiting Peptide (RIP) and Derivatives as Potential Tools for the Treatment of S. aureus Biofilm Infections.
Ciulla M; Di Stefano A; Marinelli L; Cacciatore I; Di Biase G
Curr Top Med Chem; 2018; 18(24):2068-2079. PubMed ID: 30345922
[TBL] [Abstract][Full Text] [Related]
13. Regulation of exoprotein gene expression by the Staphylococcus aureus cvfB gene.
Matsumoto Y; Kaito C; Morishita D; Kurokawa K; Sekimizu K
Infect Immun; 2007 Apr; 75(4):1964-72. PubMed ID: 17283102
[TBL] [Abstract][Full Text] [Related]
14. In vitro production of panton-valentine leukocidin among strains of methicillin-resistant Staphylococcus aureus causing diverse infections.
Hamilton SM; Bryant AE; Carroll KC; Lockary V; Ma Y; McIndoo E; Miller LG; Perdreau-Remington F; Pullman J; Risi GF; Salmi DB; Stevens DL
Clin Infect Dis; 2007 Dec; 45(12):1550-8. PubMed ID: 18190315
[TBL] [Abstract][Full Text] [Related]
15. Platelet-binding domains in 2 fibrinogen-binding proteins of Staphylococcus aureus identified by phage display.
Heilmann C; Herrmann M; Kehrel BE; Peters G
J Infect Dis; 2002 Jul; 186(1):32-9. PubMed ID: 12089659
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
Balaban N; Cirioni O; Giacometti A; Ghiselli R; Braunstein JB; Silvestri C; Mocchegiani F; Saba V; Scalise G
Antimicrob Agents Chemother; 2007 Jun; 51(6):2226-9. PubMed ID: 17371825
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting platelets aggregation could aggravate the acute infection caused by Staphylococcus aureus.
Zhang X; Liu Y; Gao Y; Dong J; Mu C; Lu Q; Shao N; Yang G
Platelets; 2011; 22(3):228-36. PubMed ID: 21265599
[TBL] [Abstract][Full Text] [Related]
18. Effects of toxin production in a murine model of Staphylococcus aureus keratitis.
Girgis DO; Sloop GD; Reed JM; O'Callaghan RJ
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2064-70. PubMed ID: 15914624
[TBL] [Abstract][Full Text] [Related]
19. [Study on in vitro and in vivo antibacterial activity of pheromonicin-SA].
Huang Y; Zhang J; Dai P; Qiu XQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):749-52. PubMed ID: 15573744
[TBL] [Abstract][Full Text] [Related]
20. Subinhibitory concentrations of phenyl lactic acid interfere with the expression of virulence factors in Staphylococcus aureus and Pseudomonas aeruginosa clinical strains.
Chifiriuc MC; Diţu LM; Banu O; Bleotu C; Drăcea O; Bucur M; Larion C; Israil AM; Lazăr V
Roum Arch Microbiol Immunol; 2009; 68(1):27-33. PubMed ID: 19507624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
